ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Shionogi's new COVID pill appears to ease omicron symptoms

Japanese drugmaker's treatment raises hopes of limiting hospitalizations

The Japanese pharmaceutical maker began clinical trails of its COVID treatment pill in September. (Photo courtesy of Shionogi)

TOKYO -- Japanese drugmaker Shionogi said Monday that preliminary laboratory studies suggest its COVID-19 tablet inhibits the severity of infections from the highly transmissible omicron variant, providing optimism that the low-cost treatment may help prevent a surge in hospitalizations.

The antiviral pill for people at the early stage of infection is designed to prevent severe illness and reduce symptoms such as fever and cough. The tablet blocks the function of an enzyme called a protease, slowing the spread of the virus.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more